Have you been diagnosed with a brain tumour? Order your free information pack.

Celebrating our award-winning researchers

Two of our funded researchers have won awards at the Society for Immunotherapy of Cancer (SITC) annual conference!

Dr Tyler Miller and Dr Mara De Martino holding their awards at the Society for Immunotherapy of Cancer Awards

Researchers Dr Tyler Miller and Dr Mara De Martino were both recognised for their high quality research in the field of cancer immunotherapy. The SITC annual meeting took place in San Diego, USA, from 1st-5th November 2023.

Dr Tyler Miller was awarded the 2023 SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship Award. This $200,000 award supports the next generation of immunotherapy experts.

Tyler has been funded by The Brain Tumour Charity since 2020, as part of our Future Leaders programme. More recently, he was awarded the first of our Junior Fellowship grants which will allow him to continue his groundbreaking work, as he discovers ways to make glioblastomas sensitive to immunotherapy. You can read more about Tyler’s current work here.

Dr Mara De Martino won a 2023 SITC Abstract Travel Award which is awarded to promising young researchers with excellent quality research that has potential to advance the research field.

Mara has recently been funded by The Brain Tumour Charity as one of our Future Leaders. She is a highly accomplished scientist in the field of tumour immunology research. Mara has a PhD from the Institute of Biology and Experimental Medicine in Argentina and has won several other awards for her impactful research. You can read more about how Mara’s work is helping to create new strategies for treating brain tumours.

Society for Immunotherapy of Cancer

The Society for Immunotherapy of Cancer is on a mission to enhance cancer patient outcomes by advancing the science, development, and application of cancer immunology and immunotherapy. This mission is driven by the core values of interaction, innovation, translation, and leadership in the field.

SITC is a not-for-profit medical professional society, comprising of influential research scientists, physician scientists, clinicians, patients, patient advocates, government representatives, and industry leaders. Its dedication lies in advancing the science and application of cancer immunotherapy to improve cancer patient outcomes. SITC aims to make the term “cure” a reality for cancer patients everywhere through educational programs that promote scientific exchange and collaboration.